Expert Interview
Discussing the potential of AstraZeneca and Ionis’ eplontersen in patients with hereditary transthyretin-mediated amyloid polyneuropathy with a neurologist.
Ticker(s): AZN, IONSInstitution: University of Utah Hospital and Clinics
- Assistant Professor of Neuromuscular Medicine at the University of Utah and Neurologic specialist in the Regional Amyloidosis Program at the Huntsman Cancer Institute.
- Manages ~12 patients with ATTRv-PN.
- Academic interests include cancer and chemotherapy related neuromuscular complications and amyloidosis.
To start us off, by way of introduction could you talk a little bit about your professional background and some details about your clinical practice?
Added By: slingshot_insightsHow many patients do you treat for the TTR amyloidosis with cardiomyopathy?
Added By: slingshot_insightsPhase III data was also recently presented. What were your thoughts on that so far?
Added By: slingshot_insightsHow does the administration differ now with eplontersen?
I was wondering your thoughts on that and whether that's reliable or will the FDA allow this as the phase III program to go forward with the filing based on this?
The technology here is based on the antisense oligonucleotide as opposed to the RNA interference. Does that give you any concern in terms of potential side effect risks?
Added By: slingshot_insightsWhat was the safety profile here? What was your impression of that?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
